Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
What is the C Rating
10.3390/ijms25021211 2 AdzikaG
Objective The aim was to compare the risk of incident AF after initiation of GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP4is), as active comparators, in patients with DM
Therefore, our study indicated that GLP-1-derived peptides offer effective pain relief without these significant adverse effects, suggesting their potential as safer alternatives for chronic pain management
14 , e2403954 (2025)
US$ 21.47
US$ 26.48
US$ 25.26
US$ 24.66
US$ 25.71
